Skip to main content
. 2013 Sep 25;73(14):1569–1586. doi: 10.1007/s40265-013-0117-0

Fig. 5.

Fig. 5

Results of the SHIFT study in patients with chronic heart failure (HF), showing the effects of ivabradine on the cumulative event curves for (a) the primary composite endpoint of cardiovascular (CV) death or hospital admission for worsening HF, (b) hospital admission for worsening HF, and (c) death from HF. HR hazard ratio. Adapted from Swedberg et al. [65]